Analysts think IRWD stock price could increase by 9%
May 05, 2025, 11:25 AM
-34.64%
What does IRWD do
Ironwood Pharmaceuticals, based in Boston, develops GI products including LINZESS for IBS-C and CIC, and is advancing treatments like apraglutide for rare GI diseases and IW-3300 for visceral pain conditions. The company, which went public in 2010, employs 267 people.
8 analysts think IRWD stock price will increase by 9.44%. The current median analyst target is $1.02 compared to a current stock price of $0.93. The lowest analysts target is $0.71 and the highest analyst target is $14.70.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.